{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Aevi+Genomic+Medicine%2C+LLC%2C+a+Cerecor+company",
    "query": {
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T08:01:24.125Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03609619",
      "title": "PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "AEVI-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 109,
      "start_date": "2018-08-17",
      "completion_date": "2018-11-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "Wayne, Pennsylvania",
      "locations": [
        {
          "city": "Wayne",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03609619"
    },
    {
      "nct_id": "NCT02811211",
      "title": "A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 1894,
      "start_date": "2016-02",
      "completion_date": "2017-01-06",
      "has_results": false,
      "last_update_posted_date": "2021-07-06",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02811211"
    },
    {
      "nct_id": "NCT03006367",
      "title": "Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "NFC-1 100 mg",
          "type": "DRUG"
        },
        {
          "name": "NFC-1 200 mg",
          "type": "DRUG"
        },
        {
          "name": "NFC-1 400 mg",
          "type": "DRUG"
        },
        {
          "name": "NFC-1 800 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 32,
      "start_date": "2017-01-07",
      "completion_date": "2017-03-06",
      "has_results": false,
      "last_update_posted_date": "2021-07-06",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 3,
      "location_summary": "Maitland, Florida • Miami, Florida • Las Vegas, Nevada",
      "locations": [
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03006367"
    },
    {
      "nct_id": "NCT03233867",
      "title": "A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 2503,
      "start_date": "2017-08-14",
      "completion_date": "2018-08-03",
      "has_results": false,
      "last_update_posted_date": "2021-07-06",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "Wayne, Pennsylvania",
      "locations": [
        {
          "city": "Wayne",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233867"
    },
    {
      "nct_id": "NCT03265119",
      "title": "PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "AEVI-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-08-28",
      "completion_date": "2018-10-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-07",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "Wayne, Pennsylvania",
      "locations": [
        {
          "city": "Wayne",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03265119"
    },
    {
      "nct_id": "NCT02286817",
      "title": "Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Attention-deficit Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "NFC-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2015-01",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286817"
    },
    {
      "nct_id": "NCT04412057",
      "title": "Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Pneumonia",
        "Acute Lung Injury",
        "ARDS"
      ],
      "interventions": [
        {
          "name": "CERC-002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2020-07-17",
      "completion_date": "2021-01-19",
      "has_results": true,
      "last_update_posted_date": "2022-03-24",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 11,
      "location_summary": "Newport Beach, California • Ft. Pierce, Florida • West Palm Beach, Florida + 8 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04412057"
    },
    {
      "nct_id": "NCT02777931",
      "title": "Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "NFC-1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 101,
      "start_date": "2016-06",
      "completion_date": "2017-02-17",
      "has_results": true,
      "last_update_posted_date": "2021-08-11",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02777931"
    },
    {
      "nct_id": "NCT02895906",
      "title": "Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "22q11.2 Deletion Syndrome"
      ],
      "interventions": [
        {
          "name": "NFC-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2016-11-28",
      "completion_date": "2017-04-20",
      "has_results": false,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02895906"
    },
    {
      "nct_id": "NCT02468414",
      "title": "TARGTEPO Treatment for Anemia in PD US Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia of End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "MDGN201 TARGTEPO",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 3,
      "start_date": "2015-06",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-10-09T08:01:24.125Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02468414"
    }
  ]
}